Product image of Metoprolol Medreg (Metoprolol Tartrate) supplied by GNH India

Metoprolol Medreg

Active Ingredient:
Metoprolol Tartrate
Origin:
EU

Metoprolol Medreg (Metoprolol Tartrate)

Metoprolol Tartrate, the active ingredient in Metoprolol Medreg, is a beta blocker presented as an oral tablet for oral use. It treats hypertension, angina pectoris, post‑myocardial infarction and chronic heart failure in adult patients. The product is manufactured to EU standards and is marketed as a generic option for cardiovascular therapy.

GNH India supplies Metoprolol Medreg as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Manufacturer / TM Owner

Medreg S.R.O.

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Metoprolol Medreg is a selective β1‑adrenergic antagonist used in several cardiovascular conditions.

  • Hypertension: lowers systolic and diastolic blood pressure, reducing the risk of stroke and myocardial infarction.
  • Angina pectoris: decreases myocardial oxygen demand, relieving chest pain during exertion.
  • Post‑myocardial infarction: improves survival by reducing arrhythmias and recurrent ischemic events.
  • Chronic heart failure: enhances ventricular function and decreases hospitalisation rates.

How It Works

  • Metoprolol Tartrate selectively blocks β1‑adrenergic receptors in cardiac tissue, inhibiting catecholamine‑induced stimulation. This reduces heart rate, myocardial contractility, and cardiac output, leading to lower blood pressure and decreased myocardial oxygen consumption, which together improve cardiovascular efficiency and symptom control.

Side Effects

Metoprolol Medreg may cause a range of adverse reactions, from mild to severe.

Common Side Effects

  • Fatigue: feeling unusually tired or weak.
  • Dizziness: light‑headedness, especially when standing quickly.
  • Bradycardia: slower than normal heart rate.
  • Cold extremities: reduced blood flow to hands and feet.
  • Gastrointestinal upset: nausea or abdominal discomfort.

Serious or Rare Side Effects

  • Severe bradycardia: heart rate dropping below 40 bpm.
  • Heart block: impaired electrical conduction requiring medical attention.
  • Acute heart failure exacerbation.
  • Bronchospasm in patients with reactive airway disease.
  • Hypotension: dangerously low blood pressure.

Precautions & Warnings

Before initiating therapy, clinicians should assess patient history and comorbidities.

  • Cardiovascular assessment: evaluate for severe bradycardia, heart block, or decompensated heart failure.
  • Respiratory caution: avoid in patients with asthma or chronic obstructive pulmonary disease unless benefits outweigh risks.
  • Diabetes monitoring: beta‑blockade may mask hypoglycaemia symptoms.
  • Concomitant drugs: review for interactions with calcium channel blockers, digoxin, or other antihypertensives.
  • Pregnancy and lactation: use only if clearly needed after risk‑benefit evaluation.
  • Store at ambient temperature: keep below 25 °C, in the original container, protected from moisture and light.

Avoid Interactions

Metoprolol can interact with several medicines, altering its efficacy or safety profile.

Major Interactions (Avoid)

  • Non‑selective beta‑blockers: additive bradycardia and hypotension.
  • Calcium channel blockers (verapamil, diltiazem): profound heart‑rate slowing and AV‑block.
  • Antidiabetic agents: may mask hypoglycaemia signs.

Moderate Interactions (Monitor Closely)

  • Digoxin: increased serum levels, risk of toxicity.
  • NSAIDs: may reduce antihypertensive effect.
  • Antidepressants (SSRIs, SNRIs): potential for enhanced bradycardia.
  • Antithyroid drugs: may exacerbate hypothyroid symptoms.

Frequently Asked Questions

Metoprolol Medreg is indicated for the management of hypertension, angina pectoris, post‑myocardial infarction care, and chronic heart failure. In each condition it helps control heart rate and blood pressure, reducing the workload on the heart and improving clinical outcomes.

Metoprolol Tartrate selectively blocks β1‑adrenergic receptors in the heart. By inhibiting the effects of adrenaline and noradrenaline, it slows the heart rate, reduces contractile force, and lowers cardiac output, which together lower blood pressure and myocardial oxygen demand.

The appropriate dose of Metoprolol Medreg is determined by the prescribing clinician based on the patient’s condition, response, and tolerability. Dosage regimens may differ for hypertension, angina, post‑MI care, or heart failure, and should follow the prescriber’s instructions.

Safety of Metoprolol Medreg in pregnancy or lactation has not been definitively established. It should only be used when the potential benefit justifies any possible risk to the fetus or infant, and the decision must be made by a qualified healthcare professional.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Metoprolol Medreg is a selective β1‑blocker, offering cardiac‑specific effects with fewer respiratory side effects compared with non‑selective agents like propranolol. Its pharmacokinetic profile provides consistent blood‑level control, making it a common choice for hypertension, angina and heart‑failure management.

Metoprolol Medreg should be stored at ambient temperature, below 25 °C, in its original packaging. Keep the product away from moisture, direct sunlight, and extreme heat to maintain stability and potency.

Metoprolol Medreg is administered orally, usually as a tablet taken with or without food. The exact timing and frequency are prescribed by the treating physician and should be followed exactly as directed.

Serious risks include severe bradycardia, heart block, hypotension, and worsening of heart failure. Patients should be monitored for signs of these conditions, especially during dose initiation or adjustment, and seek immediate medical attention if symptoms arise.

Metoprolol Medreg is contraindicated in patients with severe bradycardia, second‑ or third‑degree atrioventricular block, cardiogenic shock, or overt heart failure decompensation. It should also be avoided in individuals with known hypersensitivity to metoprolol or any component of the formulation.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Metoprolol Tartrate

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT